Vaylen vs Ondra Health
Two GLP-1 desks, one scoreboard. We put Vaylen and Ondra Health head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Too close to call on the Brief Score.
Vaylen and Ondra Health are level at 87/100. The scores won't separate them, so the pick comes down to fit: Vaylen for readers who want brand, compounded and oral options from one accredited nationwide desk without a premium sticker. Ondra Health for value-focused readers who refuse to trade accreditation or nationwide reach for a low price.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Vaylen | Ondra Health | |
|---|---|---|
| Brief Score | 87/100 (B+) | 87/100 (B+) |
| Semaglutide | $179/mo | $93/mo |
| Tirzepatide | $239/mo | $166/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.
Ondra Health: $93 sema / $166 tirz — the lowest accredited nationwide line we track; brand access + LegitScript.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.